Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | HCN1 | O60741 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23623294 | 0.90 | KCNK3 (0.45) | KCNK3KCNK9ROCK2ROCK1HCN1 | |
| SCHEMBL23623254 | 0.88 | KCNK3 (0.47) | KCNK3KCNK9ROCK2ROCK1HCN1 | |
| SCHEMBL23623350 | 0.88 | HSD17B13 (0.40) | KCNK3KCNK9HCN1LMNAMAPT | |
| SCHEMBL23623255 | 0.86 | KCNK3 (0.49) | KCNK3KCNK9ROCK2ROCK1HCN1 | |
| SCHEMBL23623811 | 0.86 | KCNK3 (0.50) | KCNK3KCNK9ROCK2ROCK1HCN1 | |
| SCHEMBL23623347 | 0.84 | MEN1 (0.40) | KCNK3KCNK9HCN1ALDH1A1LMNA | |
| SCHEMBL23623293 | 0.83 | HPGD (0.43) | KCNK3KCNK9HCN1HPGDALDH1A1 | |
| SCHEMBL23611752 | 0.82 | CLK1 (0.48) | KCNK3KCNK9ROCK2ROCK1CLK1 | |
| SCHEMBL23623235 | 0.82 | HPGD (0.49) | KCNK3KCNK9ROCK2ROCK1CLK1 | |
| SCHEMBL23623295 | 0.82 | KCNK3 (0.48) | KCNK3KCNK9ROCK2ROCK1HCN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091590-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BERG LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| WO-2021138540-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | BERG LLC (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091447-B2 | UBE2K modulators and methods for their use | UBE2N, UBE2B, UBE2E1 | KCNK3 2414/4885KCNK9 2438/4885ROCK2 2732/4885 |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | KCNK3 2414/4885KCNK9 2438/4885ROCK2 2732/4885 |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | KCNK3 2414/4885KCNK9 2438/4885ROCK2 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.